Psyched Wellness Raises $6.6 Million In Bought Deal Financing

Psyched Wellness (CSE: PSYC) has closed its previously announced private placement. The company managed to raise an impressive $6.6 million under the financing, a sizeable increase from the initial $3.0 million that was to be raised under the financing.

The offering saw a total of 21.3 million units of the company sold at a price of $0.31 per unit. Each unit consists of one common share and one common share purchase warrant, with each warrant valid for a period of three years from the date of issuance with an exercise price of $0.43 per share.

Warrants issued under the offering are also subject to an acceleration clause, whereby the company can accelerate the expiry if the equity trades above $0.70 for a period of five days on a volume weighted basis.

Proceeds from the offering are to be used to fully fund the pre-clinical trials of the firms proprietary amanita muscaria extract, known as AME-1, as well as to continue researching the compound and its potential for people suffering from mental and physical health issues. Proceeds are also to be used for general corporate purposes.

Psyched Wellness last traded at $0.55 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Altamira Gold Encounters Porphyritic Intrusive Rocks In Initial Scout Drilling At Regional Targets

Related News

Psyched Wellness Successfully Extracts Psychedelic Mushroom

Psyched Wellness (CSE: PSYC) has successfully completed its first extraction of the amanita muscaria mushroom....

Tuesday, December 15, 2020, 07:23:08 AM

Psyched Wellness Announces Study On Muscimol Antioxidant and Anti-Inflammatory Properties

Psyched Wellness (CSE: PSYC) has begun yet another study related to that of the Amanita...

Wednesday, January 6, 2021, 07:48:08 AM

Psyched Wellness Completes First Step In Study Identifying Potential Of Muscimol

Psyched Wellness (CSE: PSYC) has completed the first step in identifying the medicinal potential of...

Thursday, January 14, 2021, 06:58:13 AM

Psyched Wellness Begins Pre-Clinical Trials Of Amanita Muscaria Mushroom

Psyched Wellness (CSE: PSYC) this morning announced that it has commenced its pre-clinical trials of...

Wednesday, December 23, 2020, 08:02:43 AM

Psychedelics: Sector Tailwinds To Come – The Daily Dive feat Psyched Wellness CEO Jeff Stevens

Starting off the short Canadian trading week this week on the Daily Dive is that...

Tuesday, May 25, 2021, 01:30:00 PM